Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
about
Anti-angiogenesis in prostate cancer: knocked down but not outThe design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agentsA phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerCirculating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.Tumor lymphangiogenesis as a potential therapeutic target.Emerging targeted therapies for castration-resistant prostate cancer.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Targeting angiogenesis for the treatment of prostate cancer.Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy.A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
P2860
Q26851183-561FDC4D-1C8F-4451-BC8B-7E1A38DE3EEEQ33872751-F044995A-F88E-4E85-A31F-FC510CFC9813Q34657338-6AC20A35-45DC-473A-9FC0-5A001EED4814Q35155251-D0CF0E74-CA94-4D76-8275-1624E8FD1EFEQ35838122-AEAC5CB4-1E96-409E-B0C8-499CA000EA45Q35999255-F7A7691F-4272-4B24-A11A-E86FF1188510Q36181578-4B5227E7-17BD-47E5-8651-DB7664289780Q37968256-62E4D440-2501-41F0-8A3C-3D139D030914Q37993137-B99C6F45-3FDD-43B1-81B8-3C0B9506CA30Q38028012-1F561D77-D9D0-4CF7-B0A8-BC3F0AABEBE5Q38116358-9C6881CC-D105-4E4B-87B6-5565A6B913BAQ38246587-A543B1DA-C83D-4DC6-A1B9-87506D32A78FQ38584742-4330CD4E-E95F-4D92-9686-84F081671092Q40120703-0104EDF3-CA0C-4732-AA63-5AC77F6610C0Q43867243-5075EE71-11DE-4D6C-A825-F01CA37665BB
P2860
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Sunitinib in combination with ...... r: a phase 1/2 clinical trial.
@ast
Sunitinib in combination with ...... r: a phase 1/2 clinical trial.
@en
type
label
Sunitinib in combination with ...... r: a phase 1/2 clinical trial.
@ast
Sunitinib in combination with ...... r: a phase 1/2 clinical trial.
@en
prefLabel
Sunitinib in combination with ...... r: a phase 1/2 clinical trial.
@ast
Sunitinib in combination with ...... r: a phase 1/2 clinical trial.
@en
P2093
P2860
P921
P356
P1433
P1476
Sunitinib in combination with ...... r: a phase 1/2 clinical trial.
@en
P2093
A J Zurita
C J Logothetis
C S Harmon
D J George
E Chow Maneval
P2860
P304
P356
10.1093/ANNONC/MDR349
P577
2011-08-05T00:00:00Z